JP2007529223A - 選択的スプライシングを用いて真核細胞においてポリペプチドマルチマーを発現するための方法および構築物 - Google Patents

選択的スプライシングを用いて真核細胞においてポリペプチドマルチマーを発現するための方法および構築物 Download PDF

Info

Publication number
JP2007529223A
JP2007529223A JP2007504008A JP2007504008A JP2007529223A JP 2007529223 A JP2007529223 A JP 2007529223A JP 2007504008 A JP2007504008 A JP 2007504008A JP 2007504008 A JP2007504008 A JP 2007504008A JP 2007529223 A JP2007529223 A JP 2007529223A
Authority
JP
Japan
Prior art keywords
vector
polypeptide
antibody
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007504008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007529223A5 (enExample
Inventor
ホリー プレンティス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Inc
Biogen Idec Inc
Biogen Idec MA Inc
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Biogen Idec Inc, Biogen Idec MA Inc, Biogen MA Inc filed Critical Biogen Inc
Publication of JP2007529223A publication Critical patent/JP2007529223A/ja
Publication of JP2007529223A5 publication Critical patent/JP2007529223A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
JP2007504008A 2004-03-15 2005-03-15 選択的スプライシングを用いて真核細胞においてポリペプチドマルチマーを発現するための方法および構築物 Pending JP2007529223A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55347804P 2004-03-15 2004-03-15
PCT/US2005/008473 WO2005089285A2 (en) 2004-03-15 2005-03-15 Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing

Publications (2)

Publication Number Publication Date
JP2007529223A true JP2007529223A (ja) 2007-10-25
JP2007529223A5 JP2007529223A5 (enExample) 2008-05-01

Family

ID=34994241

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007504008A Pending JP2007529223A (ja) 2004-03-15 2005-03-15 選択的スプライシングを用いて真核細胞においてポリペプチドマルチマーを発現するための方法および構築物

Country Status (10)

Country Link
US (2) US7569362B2 (enExample)
EP (1) EP1733034A4 (enExample)
JP (1) JP2007529223A (enExample)
KR (1) KR20070004026A (enExample)
CN (1) CN1961071A (enExample)
AU (1) AU2005222963B2 (enExample)
BR (1) BRPI0508862A (enExample)
CA (1) CA2559280A1 (enExample)
IL (1) IL178051A (enExample)
WO (1) WO2005089285A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016514477A (ja) * 2013-03-30 2016-05-23 ウーシャ バイオテック リミテッド 哺乳動物細胞内で生物活性タンパク質を発現させるための方法および構築物
JP2016528896A (ja) * 2013-08-06 2016-09-23 グレンマーク ファーマシューティカルズ， エセ．アー． 真核細胞においてポリペプチドを発現させるための発現構築物及び方法
JP2022511227A (ja) * 2018-07-17 2022-01-31 ニューロマイオン インコーポレイテッド Ｉｇｆ－１異型体を発現させるｄｎａコンストラクトを用いた神経病症の治療
JP2022546408A (ja) * 2019-08-30 2022-11-04 ベイラー カレッジ オブ メディスン 遺伝子発現を調節するためのシステム
JP2024500194A (ja) * 2021-11-26 2024-01-05 勁帆生物医薬科技（武漢）有限公司 重複オープンリーディングフレームを含む遺伝子の発現カセット、及び昆虫細胞におけるこの発現カセット使用

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2355459B (en) * 1999-11-29 2001-09-26 Isis Innovation A dominant conditional lethal genetic system
GB2402675B (en) * 2003-05-12 2008-02-20 Oxitec Ltd Resistance dilution
GB2403475B (en) * 2003-07-01 2008-02-06 Oxitec Ltd Stable integrands
GB2404382B (en) 2003-07-28 2008-01-30 Oxitec Ltd Pest control
CA2559280A1 (en) * 2004-03-15 2005-09-29 Biogen Idec Ma Inc. Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing
US20090183269A1 (en) * 2006-02-10 2009-07-16 Oxitec Limited Gene expression system using alternative splicing in insects
GB2443186A (en) 2006-10-25 2008-04-30 Oxitec Ltd Expression system for mediating alternative splicing
EA200802061A1 (ru) 2006-03-28 2009-04-28 Байоджен Айдек Эмэй Инк. Антитело или его фрагмент, специфично связывающееся с рецептором 1 инсулиноподобного фактора роста (igf-r1) (варианты), композиция на его основе, полинуклеотид, кодирующий вариабельную область антитела (варианты), содержащие полинуклеотид композиция (варианты) и вектор, содержащая вектор клетка-хозяин (варианты), способ продуцирования антитела или его фрагмента (варианты) и способ лечения гиперпролиферативного заболевания у животного организма
EP2018430A1 (en) * 2006-05-16 2009-01-28 Millegen Method for expressing polypeptides in eukaryotic cells using alternative splicing
KR101202498B1 (ko) * 2006-05-17 2012-11-16 에프. 호프만-라 로슈 아게 폴리펩티드 생성 세포
US20080045419A1 (en) * 2006-08-18 2008-02-21 University Of North Texas Health Science Center At Fort Worth Screening Assay
MX2010004007A (es) * 2007-10-15 2010-06-15 Chugai Pharmaceutical Co Ltd Metodo para la produccion de un anticuerpo.
WO2009059235A2 (en) * 2007-11-01 2009-05-07 Facet Biotech Corporation Immunoglobulin display vectors
KR100907221B1 (ko) * 2009-01-22 2009-07-10 한국과학기술원 새로운 조성의 황색 발광 Ｃｅ3+부활 칼슘 실리케이트 황색형광체를 포함하는 백색 발광 다이오드
WO2011125833A1 (ja) 2010-03-31 2011-10-13 学校法人 慶應義塾 生体分子相互作用解析ツールの構成とそれを用いた解析方法
US9220774B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Methods of treating cancer by administering anti-GPR49 antibodies
AU2012332588B2 (en) 2011-11-01 2017-09-07 Bionomics, Inc. Methods of blocking cancer stem cell growth
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
AU2012332587B2 (en) 2011-11-01 2017-02-23 Bionomics, Inc. Antibodies and methods of treating cancer
SG10201805622QA (en) * 2011-12-22 2018-08-30 Hoffmann La Roche Expression Vector Organization, Novel Production Cell Generation Methods And Their Use For The Recombinant Production Of Polypeptides
GB2500113A (en) 2012-03-05 2013-09-11 Oxitec Ltd Arthropod male germline gene expression system
GB201303932D0 (en) 2013-03-05 2013-04-17 Oxitec Ltd Muscle actin promoter
EP3126397B1 (en) 2014-04-04 2020-01-29 Bionomics, Inc. Humanized antibodies that bind lgr5
GB2526867A (en) 2014-06-05 2015-12-09 Oxitec Ltd Gene expression system
AU2017239038B2 (en) 2016-03-22 2024-06-27 Bionomics Inc Administration of an anti-LGR5 monoclonal antibody
WO2018029534A1 (en) 2016-08-12 2018-02-15 Oxitec Ltd. A self-limiting, sex-specific gene and methods of using
EP3472198B1 (en) 2016-09-29 2020-03-04 H. Hoffnabb-La Roche Ag Improved method for selecting polypeptide producing cells
AR117409A1 (es) 2018-03-29 2021-08-04 Oxitec Ltd Noctuidas autolimitantes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024596A1 (en) * 1997-11-12 1999-05-20 Valentis, Inc. Expression plasmids for multiepitope nucleic acid-based vaccines

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2759053A1 (de) * 1977-12-30 1979-07-12 Uhlin Verfahren zum herstellen von genprodukten von plasmid-dns
GB2048894A (en) * 1979-05-11 1980-12-17 Gist Brocades Nv Plasmid
JPS58192900A (ja) * 1982-05-04 1983-11-10 Ajinomoto Co Inc 複合プラスミド
US5043270A (en) * 1989-03-31 1991-08-27 The Board Of Trustees Of The Leland Stanford Junior University Intronic overexpression vectors
SG84484A1 (en) * 1991-02-25 2001-11-20 Ciba Geigy Ag Improved yeast vectors
US5587308A (en) * 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5561053A (en) * 1994-08-05 1996-10-01 Genentech, Inc. Method for selecting high-expressing host cells
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US6900010B2 (en) * 1999-01-25 2005-05-31 Musc Foundation For Research Development Compositions and methods for detecting human immunodeficiency virus
WO2000075342A1 (fr) * 1999-06-04 2000-12-14 Nippon Institute For Biological Science Nouveau vecteur plasmidique
JP2006512061A (ja) * 2002-11-14 2006-04-13 ジェネンテック・インコーポレーテッド イントロン融合コンストラクトおよび高発現産生細胞系を選択するための使用方法
MXPA05008523A (es) * 2003-02-14 2005-10-20 Biogen Idec Inc Un casete de expresion y vector para la expresion transitoria o estable de moleculas exogenas.
CA2559280A1 (en) * 2004-03-15 2005-09-29 Biogen Idec Ma Inc. Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024596A1 (en) * 1997-11-12 1999-05-20 Valentis, Inc. Expression plasmids for multiepitope nucleic acid-based vaccines

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016514477A (ja) * 2013-03-30 2016-05-23 ウーシャ バイオテック リミテッド 哺乳動物細胞内で生物活性タンパク質を発現させるための方法および構築物
JP2016528896A (ja) * 2013-08-06 2016-09-23 グレンマーク ファーマシューティカルズ， エセ．アー． 真核細胞においてポリペプチドを発現させるための発現構築物及び方法
JP2020202840A (ja) * 2013-08-06 2020-12-24 イクノス サイエンシズ エスエー 真核細胞においてポリペプチドを発現させるための発現構築物及び方法
JP2022177131A (ja) * 2013-08-06 2022-11-30 イクノス サイエンシズ エスエー 真核細胞においてポリペプチドを発現させるための発現構築物及び方法
JP2022511227A (ja) * 2018-07-17 2022-01-31 ニューロマイオン インコーポレイテッド Ｉｇｆ－１異型体を発現させるｄｎａコンストラクトを用いた神経病症の治療
JP7413629B2 (ja) 2018-07-17 2024-01-16 ヘリックスミス カンパニー， リミテッド Ｉｇｆ－１異型体を発現させるｄｎａコンストラクトを用いた神経病症の治療
JP2022546408A (ja) * 2019-08-30 2022-11-04 ベイラー カレッジ オブ メディスン 遺伝子発現を調節するためのシステム
JP7737152B2 (ja) 2019-08-30 2025-09-10 ベイラー カレッジ オブ メディスン 遺伝子発現を調節するためのシステム
JP2024500194A (ja) * 2021-11-26 2024-01-05 勁帆生物医薬科技（武漢）有限公司 重複オープンリーディングフレームを含む遺伝子の発現カセット、及び昆虫細胞におけるこの発現カセット使用
JP7560896B2 (ja) 2021-11-26 2024-10-03 勁帆生物医薬科技（武漢）有限公司 重複オープンリーディングフレームを含む遺伝子の発現カセット、及び昆虫細胞におけるこの発現カセット使用

Also Published As

Publication number Publication date
AU2005222963B2 (en) 2009-10-29
KR20070004026A (ko) 2007-01-05
WO2005089285A2 (en) 2005-09-29
US7569362B2 (en) 2009-08-04
AU2005222963A1 (en) 2005-09-29
IL178051A (en) 2010-12-30
US20100009410A1 (en) 2010-01-14
EP1733034A4 (en) 2010-01-20
CN1961071A (zh) 2007-05-09
CA2559280A1 (en) 2005-09-29
BRPI0508862A (pt) 2007-09-04
US20050221430A1 (en) 2005-10-06
WO2005089285A3 (en) 2006-01-19
IL178051A0 (en) 2006-12-31
EP1733034A2 (en) 2006-12-20

Similar Documents

Publication Publication Date Title
US7569362B2 (en) Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing
US11046975B2 (en) Bicistronic expression vector for antibody expression and method for producing antibody using same
CA2368734C (en) Method for preparing monoclonal antibody
KR20220012231A (ko) 완전-인간 번역 후 변형된 항체 치료제
KR20140032992A (ko) Ｃｓｆ－1ｒ에 대한 항체
KR20010012441A (ko) 화합물
CN107827989A (zh) 靶向骨髓瘤bcma抗原的转基因t细胞及其制备方法与应用
KR20200131335A (ko) 항-fam19a5 항체의 아데노-연관 바이러스(aav) 전달
CN110551214A (zh) 一种人源化抗Periostin单克隆抗体、及其制备方法和应用
WO2019128994A1 (zh) 稳定表达PD-1抗体的Muc1特异性CAR-T细胞及其用途
Jiang et al. Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers
TW201231650A (en) Process for production of protein
CN116528892A (zh) 用于眼部适应症的载体化抗TNF-α抗体
CN110563841A (zh) 一种人源化抗Grb2单克隆抗体、及其制备方法和应用
AU2002353662B2 (en) Production of F(ab')2 fragments in mammalian cells
CN111206043A (zh) 一种改进的pb转座子系统及其用途
JP5073653B2 (ja) 高レベルのタンパク質を産生する発現ベクター及び方法
CN1777672A (zh) 包含具有人恒定区的肿瘤治疗性全抗体基因的重组病毒及其用途
JP7755725B2 (ja) Ｆｃｒｎを特異的に認識する抗体およびその使用
TW202241943A (zh) Tau特異性抗體基因療法組合物、方法及其用途
WO2019129142A1 (zh) 自分泌CD40抗体且靶向ErbB受体家族的CAR-T细胞及其用途
CN116457373A (zh) 用于眼部适应症的载体化TNF-α拮抗剂
TW202309281A (zh) 用於治療與血管生成相關的眼部疾病的組合物和方法
MXPA06010445A (en) Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing
WO2024054993A1 (en) Vector constructs for delivery of nucleic acids encoding therapeutic anti-ctla4 antibodies and methods of using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111025